Does the placebo response need to be considered in clinical trials for COVID-19 vaccines and treatments?
The search for drugs to treat and prevent SARS-CoV-2 infection is ongoing, with more than 1200 drugs in the pipeline and more 3,200 clinical trials planned or initiated as of 21 September 2020 (GlobalData). The success of these studies, however, may be at risk due to an invisible threat – the placebo response.Read More
This webinar aimed to explain the impact of COVID-19 crisis on patient behavior in ongoing clinical trials, introduce the application of COV-IQ technology and describe how it may improve interpretation of clinical trial results. During the webinar, questions from the audience were addressed; the main ones are compiled below.Read More
As one might expect, the life changes are a source of stress, and the data supports this assertion. In fact, a recent analysis by Express Scripts also showed an increase in prescriptions for medications to treat anxiety, depression and insomnia as a result of the pandemic.Read More
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by both motor and non-motor features. The disease has a significant clinical impact on patients, families, and caregivers through its progressive degenerative effects on mobility and muscle control.Read More
Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more common than rheumatoid arthritis (RA).Read More
Are clinical trials patients’ reactions to crisis related to their personality? Application to the COVID-19 pandemic.
Not only are patient visits to clinical sites more difficult (or impossible), patients are also dealing with uncertainty, stress and anxiety. While keeping ongoing trials running is a top objective for many, understanding how this myriad of factors will affect trial data is paramount.Read More
Evidence has accumulated in recent years that the placebo response is a significant issue in evaluating efficacy of drugs for rheumatoid arthritis (RA). RA is a chronic disease characterized by inflammatory synovitis and progressive joint destruction.Read More
While the opioid crisis may be creating opportunity for development of novel therapies to treat chronic pain, drug development in this area has historically struggled. According to a BIO report released in 2018, only two novel NCEs were approved for pain indications from 2007-2017 while other analgesia approvals during this period were reformulations of existing compounds or drugs with approval history prior to 2007.Read More
As 2019 came to a close and we begin a new decade, it’s an excellent opportunity to evaluate and learn from the past year and set a course for the future. Tools4Patient (T4P) had a momentous year as we increased on our focus on the commercialization of Placebell©™ – T4P’s innovative approach to reduce the impact of theRead More